Search the GHTC website

Global health R&D delivers for South Carolina

US government investment in global health R&D has delivered

$30.1 million
to South Carolina research institutions
450+ new jobs
for South Carolina
South Carolina's top USG-funded global health R&D institutions

South Carolina's top USG-funded global health R&D institutions

Clemson University
$15.4 million
Medical University of South Carolina
$7.9 million
University of South Carolina at Columbia
$4.3 million
$1.4 million
Alpha Genesis, Inc.
$1.1 million

South Carolina's top areas of global health R&D by USG funding

Neglected tropical diseases
Kinetoplastid diseases
Snakbite envenoming
Reproductive health
Salmonella infections
Multi-disease/health area R&D
Hepatitis C
Global health R&D at work in South Carolina

Clemson University researchers are seeking new treatments for sleeping sickness and leishmaniasis, two neglected parasitic diseases that threaten millions worldwide. The former, transmitted by the tsetse fly, leads to neurological and psychiatric issues, and the latter, carried by sandflies, causes disfiguring skin lesions and deadly spleen and liver problems in severe cases. The scientists are screening tens of thousands of molecules in the hopes of identifying ones capable of interfering with the parasite’s abilities to process sugar, their food and energy source. Molecules that show promise will be evaluated as potential drugs. If successful, the work could also lead to new treatments for other parasitic infections, including Chagas disease.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: FDA/Michael J. Ermarth